Yamasaki Makoto, Miyata Hiroshi, Miyazaki Yasuhiro, Takahashi Tsuyoshi, Kurokawa Yukinori, Nakajima Kiyokazu, Takiguchi Shuji, Mori Masaki, Doki Yuichiro
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan,
Ann Surg Oncol. 2014 Sep;21(9):2850-6. doi: 10.1245/s10434-014-3696-4. Epub 2014 Apr 14.
The 7th edition of the Union for International Cancer Control-TNM (UICC-TNM) classification for esophageal carcinoma made considerable modifications to the definition of N-staging by the number of involved lymph nodes and the regional node boundary. There were few validations of the regional boundary. We evaluated the nodal status of this classification for esophageal squamous cell carcinoma (ESCC).
There were 665 patients reviewed who had ESCC and underwent esophagectomy between 1997 and 2012. We evaluated the impact of the location of lymph node metastasis on overall survival.
There were 414 patients (61.7 %) who had lymph node metastases. The overall 5-year survival rate was 54.7 %. There were no significant differences in survival among N2, N3, and M1 patients. Cox regression analysis revealed that common hepatic or splenic node involvements (P = 0.001), pT stage (P = 0.0002), and pN stage (P < 0.0001) were independent predictors of survival, but supraclavicular node involvement (P = 0.29) was not. We propose a modified nodal status that designates supraclavicular node as regional: m-N0 (5-year survival = 79 %; n = 251); m-N1 (5-year = 56 %; n = 212); m-N2 (5-year = 30 %; n = 114); m-N3 (5-year = 18 %; n = 52); m-M1 (5-year = 6.2 %; n = 36). This modified nodal staging predicts survival better than the current staging system.
The modification of supraclavicular lymph node from nonregional to regional in the 7th UICC classification of ESCC may allow for better stratification of overall survival.
国际癌症控制联盟-肿瘤学分期手册(UICC-TNM)第7版食管癌分类对N分期的定义在受累淋巴结数量和区域淋巴结边界方面做了重大修改。区域边界的验证很少。我们评估了该分类对食管鳞状细胞癌(ESCC)的淋巴结状态。
回顾了1997年至2012年间665例接受食管癌切除术的ESCC患者。我们评估了淋巴结转移部位对总生存的影响。
414例患者(61.7%)有淋巴结转移。总体5年生存率为54.7%。N2、N3和M1患者的生存率无显著差异。Cox回归分析显示,肝总或脾门淋巴结受累(P = 0.001)、pT分期(P = 0.0002)和pN分期(P < 0.0001)是生存的独立预测因素,但锁骨上淋巴结受累(P = 0.29)不是。我们提出一种改良的淋巴结状态,将锁骨上淋巴结指定为区域淋巴结:m-N0(5年生存率 = 79%;n = 251);m-N1(5年 = 56%;n = 212);m-N2(5年 = 30%;n = 114);m-N3(5年 = 18%;n = 52);m-M1(5年 = 6.2%;n = 36)。这种改良的淋巴结分期比当前分期系统能更好地预测生存。
在ESCC的第7版UICC分类中,将锁骨上淋巴结从非区域淋巴结改为区域淋巴结可能有助于更好地对总生存进行分层。